CLEAR·OCEAN

Larimar Therapeutics, Inc. (LRMR) — Insider Activity & Signal

Healthcare · Biotechnology · Market cap $366M · $4.28 · 52-week range $2.71–$6.42

Recent insider buying

Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.

DateInsiderRoleSharesPriceValueSource
2026-07-06Hamilton Thomas Edwarddirector50,000$3.34$166,890SEC Form 4
2026-02-27Flynn James Edirector, 10 percent owner, other: * Director by Deputization1,084,012$5.00$5,420,060SEC Form 4
2026-02-27Flynn James Edirector, 10 percent owner, other: * Director by Deputization1,084,010$5.00$5,420,050SEC Form 4
2026-02-27Flynn James Edirector, 10 percent owner, other: * Director by Deputization831,978$5.00$4,159,890SEC Form 4
2026-02-27Flynn James Edirector, 10 percent owner, other: * Director by Deputization2,000,000$5.00$10,000,000SEC Form 4
2026-02-27Hamilton Thomas Edwarddirector100,000$5.00$500,000SEC Form 4
2026-02-27THOMAS FRANK Edirector5,000$5.00$25,000SEC Form 4
2026-02-27SHERMAN JEFFREY Wdirector5,000$5.00$25,000SEC Form 4

Financial health

Altman Z-Score -0.49 · Piotroski F-Score 1/9 · Cash $137M · Debt $4M

ClearOcean signal read

ClearOcean's model currently scores LRMR as a watchlist-level signal (5/10), based on the insider, fundamental and risk data above. This is a factual model output, not advice.

Sources & further reading

Last updated July 13, 2026.

ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.